Clinical Trial

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-07-31
Trial Details
NCT Number NCT07092865
Lead Sponsor GlaxoSmithKline
Conditions Respiratory Syncytial Virus Infections
Enrollment 168 participants
Start Date 2025-08-06
Primary Completion 2027-01-12 (estimated)
Study Completion 2027-07-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-30